{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:41:19Z","timestamp":1770741679345,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.htct.2021.09.003","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T13:33:50Z","timestamp":1637069630000},"page":"S22-S29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S2","title":["Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma"],"prefix":"10.1016","volume":"43","author":[{"given":"Alvaro J.","family":"Alencar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre V.","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego V.","family":"Cl\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Aur\u00e9lio","family":"Salvino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Perini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celso","family":"Arrais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ot\u00e1vio","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo Carvalho","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iago","family":"Colturato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Chiattone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayr Schmidt","family":"Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Nabhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato L.","family":"Guerino-Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-2578","authenticated-orcid":false,"given":"Carlos S.","family":"Chiattone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.htct.2021.09.003_bib0001","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.htct.2021.09.003_bib0002","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.htct.2021.09.003_bib0003","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","article-title":"Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project","volume":"101","author":"Perry","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.htct.2021.09.003_bib0004","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.htct.2021.09.003_bib0005","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.htct.2021.09.003_bib0006","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.htct.2021.09.003_bib0007","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/annonc\/mds054","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed\/refractory mantle cell lymphoma: a multicenter experience","volume":"23","author":"Le Gouill","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"10","key":"10.1016\/j.htct.2021.09.003_bib0008","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.htct.2021.09.003_bib0009","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hon.2844","article-title":"Optimizing CAR T cell therapy in lymphoma","volume":"39","author":"Qualls","year":"2021","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.htct.2021.09.003_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.htct.2021.09.003_bib0011","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10254","key":"10.1016\/j.htct.2021.09.003_bib0012","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.htct.2021.09.003_bib0013","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.htct.2021.09.003_bib0014","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.htct.2021.09.003_bib0015","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.htct.2021.09.003_bib0016","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.htct.2021.09.003_bib0017","first-page":"40","article-title":"Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed\/Refractory (R\/R) Indolent Non-Hodgkin Lymphoma (iNHL)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.htct.2021.09.003_bib0018","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.htct.2021.09.003_bib0019","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1080\/10428194.2020.1864349","article-title":"Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis","volume":"62","author":"Mian","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.htct.2021.09.003_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-136158","article-title":"Safety and preliminary efficacy in patients with relapsed\/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in transcend NHL 001","volume":"136","author":"Palomba","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.htct.2021.09.003_bib0021","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.hoc.2020.06.010","article-title":"Allogeneic transplantation and chimeric antigen receptor-engineered T-Cell therapy for relapsed or refractory mantle cell lymphoma","volume":"34","author":"Gauthier","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.htct.2021.09.003_bib0022","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/cancers13020291","article-title":"Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy","volume":"13","author":"Marangon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.htct.2021.09.003_bib0023","doi-asserted-by":"crossref","unstructured":"Martin P, Wang M, Kumar A, Qi K, Daly K, Parisi L, et\u00a0al. Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice. 2021 ASCO Annual Meeting. Abstract #:7504","DOI":"10.1200\/JCO.2021.39.15_suppl.7504"},{"key":"10.1016\/j.htct.2021.09.003_bib0024","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.htct.2021.09.003_bib0025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2021.09.003_bib0026","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.htct.2021.09.003_bib0027","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.htct.2021.09.003_bib0028","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.htct.2021.09.003_bib0029","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.htct.2021.09.003_bib0030","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed\/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant [Internet]"},{"issue":"5","key":"10.1016\/j.htct.2021.09.003_bib0031","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1200\/JCO.20.01751","article-title":"Autologous stem cell transplantation in the management of relapsed Non-Hodgkin Lymphoma","volume":"39","author":"Alencar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.htct.2021.09.003_bib0032","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2021.09.003_bib0033","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.htct.2021.09.003_bib0034","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.htct.2021.09.003_bib0035","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"issue":"7547","key":"10.1016\/j.htct.2021.09.003_bib0036","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"issue":"DEC","key":"10.1016\/j.htct.2021.09.003_bib0037","article-title":"Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation","volume":"8","author":"Buchwald","year":"2018","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.htct.2021.09.003_bib0038","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T Cell therapy with axicabtagene ciloleucel in diffuse large B-Cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.htct.2021.09.003_bib0039","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"10.1016\/j.htct.2021.09.003_bib0040","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1182\/bloodadvances.2020003391","article-title":"C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas","volume":"4","author":"Jacobson","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.htct.2021.09.003_bib0041","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/bloodadvances.2020004155","article-title":"Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas","volume":"5","author":"Liebers","year":"2021","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.htct.2021.09.003_bib0042","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.htct.2021.09.003_bib0043","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/13696998.2019.1582059","article-title":"CAR T-cells: costs, comparisons, and commentary","volume":"22","author":"Hay","year":"2019","journal-title":"J Med Econ"},{"issue":"9","key":"10.1016\/j.htct.2021.09.003_bib0044","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","article-title":"Value and affordability of CAR T-cell therapy in the United States","volume":"55","author":"Fiorenza","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.htct.2021.09.003_bib0045","article-title":"Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries","volume":"8","author":"J\u00f8rgensen","year":"2020","journal-title":"J Mark access Heal policy"},{"issue":"24","key":"10.1016\/j.htct.2021.09.003_bib0046","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-Cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137921001371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137921001371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:34:00Z","timestamp":1762868040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137921001371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":46,"alternative-id":["S2531137921001371"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2021.09.003","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2021.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular.","name":"copyright","label":"Copyright"}]}}